StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
SAGE Therapeutics (SAGE): Primary Endpoints in Both Phase III PPD Trials Met - Suntrust
November 9, 2017 7:17 AM
SunTrust Robinson Humphrey analyst, Edward Nash, reiterated his Buy rating on shares of Sage Therapeutics (NASDAQ: SAGE) after the company ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Chardan Capital Markets Upgrades Sage Therapeutics (SAGE) to Buy
November 10, 2017 8:16 AM
Sage Therapeutics (SAGE) PT Raised to $135 at Cowen
November 9, 2017 3:20 PM
Sage Therapeutics (SAGE) PT Raised to $105 at Stifel
November 9, 2017 12:43 PM
Sage Therapeutics (SAGE) PT Raised to $123 at Leerink Partners
November 9, 2017 12:13 PM
Sage Therapeutics (SAGE) PT Raised to $100 at Needham & Company
November 9, 2017 11:34 AM
Sage Therapeutics (SAGE) Hits 'Very Significant Milestone' - BMO
November 9, 2017 10:12 AM
